Abstract
To the Editor.— Ciprofloxacin by oral administration has recently gained considerable popularity in the treatment of serious deep-seated infections in clinically stable patients because of its intense microbiological activity against most Enterobacteriaceae and Pseudomonas aeruginosa organisms and its excellent bioavailability, at least in healthy volunteers. There remains, however, a paucity of bioavailability data on ciprofloxacin and other fluoroquinolones in ill patients, particularly those who are receiving other drugs. It has been demonstrated in normal volunteers that aluminum- and magnesium-containing compounds (eg, antacids) decrease the mean peak concentrations of a single 500-mg dose of ciprofloxacin from 1.7 to 0.1 μg/mL and urine recovery from 24% to 2.1%, presumably because of chelate formation. 1 Morever, in a recent report, 2 sucralfate, an aluminum-containing compound, significantly reduced the bioavailability of norfloxacin. Here, we report on six elderly patients who received 750 mg of ciprofloxacin by mouth, one of whom was also receiving 1
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
